MedTrace Logo

Evaluation of IL-33 in Patients With the Acute Ischemic Stroke

NCT03948802 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-08-15

No results posted yet for this study

Summary

Aim of the study is to evaluate the usefulness of interleukin 33 in the blood plasma in patients with the acute ischemic stroke of the brain in relation to mode of treatment (thrombolysis, thrombectomy, no treatment), risk factors in correlation with other inflammatory state markers (hsCRP, morphology with smear ). Blood is collected on the first and seventh days of stroke.

The purpose is to clarify utility of IL 33 as a biomarker of acute stroke.

Conditions

Interventions

DIAGNOSTIC_TEST

Interleukine 33 test in blood plasma

ELISA test for Interleukin 33

Sponsors & Collaborators

  • Jan Biziel University Hospital No 2 in Bydgoszcz

    lead OTHER

Principal Investigators

  • Paweł Sokal · Jan Biziel University Hospital Collegium Medicum Nicolaus Copernicus University

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2023-12-31
Completion
2024-03-06

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03948802 on ClinicalTrials.gov